Vilazodone hydrochloride


Vilazodone hydrochloride

Latest News

loading GIF

Drug updated on 4/10/2024

Dosage FormTablet (oral; 10 mg, 20 mg, 40 mg)
Drug ClassAntidepressants
Ongoing and
Completed Studies


  • For the treatment of major depressive disorder (MDD) in adults.

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Vilazodone hydrochloride (Viibryd) is indicated for the treatment of major depressive disorder (MDD) in adults, but it may not be superior to other antidepressants such as amitriptyline, citalopram, and vortioxetine.
  • Three studies reviewed compared vilazodone with 20 other antidepressants in terms of efficacy and safety.
  • The first study suggests that desvenlafaxine, paroxetine, venlafaxine, and vortioxetine are more preferable due to their reasonable efficacy, acceptability, and tolerability profiles.
  • The second study's findings on safety concerns and toxicity profile indicate that vilazodone poses serious risks, especially its potential to cause serotonin syndrome and seizures even at minimal doses in children, which highlights a concern for its use particularly among populations at risk for overdose or households with young children.
  • The third study evaluated vilazodone‚Äôs pharmacokinetics and pharmacodynamics along with clinical utility for treating MDD and GAD. It suggested that while Viibryd is superior to placebo, it does not offer significant advantages over SSRIs or other currently used antidepressants, thus suggesting it as a second- or third-line treatment option only.
  • Although effective against placebo, Viibryd does not seem to remarkably surpass several other antidepressant drugs available today, making further research necessary, especially larger studies, to fully understand this drug's place within MDD and GAD treatments amongst a plethora of available antidepressant options.